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Abstract
Cytochomosome P450 enzymes (CYP) are heme-containing monooxygenases responsible for oxidative metabolism of many
exogenous and endogenous compounds including drugs. The species difference of CYP limits the extent to which data
obtained from animals can be translated to humans in pharmacodynamics or pharmacokinetics studies. Transgenic
expression of human CYP in animals lacking or with largely reduced endogenous CYP counterparts is recognized as an ideal
strategy to correct CYP species difference. CYP3A is the most abundant CYP subfamily both in human and mammals. In this
study, we designed a microRNA-based shRNA (miR-shRNA) simultaneously targeting four members of mouse CYP3A
subfamily (CYP3A11, CYP3A16, CYP3A41 and CYP3A44), and transgenic mice expressing the designed miR-shRNA were
generated by lentiviral transgenesis. Results showed that the CYP3A expression level in transgenic mice was markedly
reduced compared to that in wild type or unrelated miR-shRNA transgenic mice, and was inversely correlated to the miR-
shRNA expression level. The CYP3A expression levels in transgenic offspring of different generations were also remarkably
lower compared to those of controls, and moreover the inhibition rate of CYP3A expression remained comparable over
generations. The ratio of the targeted CYP3A transcriptional levels was comparable between knockdown and control mice
of the same gender as detected by RT-PCR DGGE analysis. These data suggested that transgenic miR-shRNA suppressed
CYP3A expression in a dose-dependent and inheritable manner, and transcriptional levels of the targeted CYP3As were
suppressed to a similar extent. The observed knockdown efficacy was further confirmed by enzymatic activity analysis, and
data showed that CYP3A activities in transgenic mice were markedly reduced compared to those in wild-type or unrelated
miR-shRNA transgenic controls (1.1160.71 vs 5.8561.74, 5.962.4; P,0.01). This work laid down a foundation to further
knock down the remaining murine CYP3As or CYPs of other subfamilies, and a basis to generate CYP knockdown animals of
other species.
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Introduction
RNA interference (RNAi) is a post transcriptional gene silencing
mechanism, which is conserved among a broad variety of
eukaryotic organisms including mammalian species [1–4]. Mam-
malian models specifically lacking target gene expression are
powerful tools for deciphering gene functions and generating bio-
medical models. Traditional method for generating gene-disrupted
animals is through ES cell-based homologous recombination.
Although this method is effective, it is limited by the low efficiency
of DNA homologous recombination, time-consuming and labor-
intensive cross strategies for obtaining homozygous mutant
individuals, and more importantly, the lack of ES cells derived
from other mammalian species limits its application to other
important mammalian model animals such as rats, pigs and
monkeys. Since RNAi is a highly conserved gene silence
mechanism, RNAi provides an alternative method for specifically
disrupting mammalian gene expression on both cell and individual
level.
By transgenic expression of shRNA molecules, mammalian
endogenous gene expression can be specifically inhibited in vivo
[5–9]. Recently, a microRNA-based shRNA (miR-shRNA) system
has been developed and utilized to effectively knock down target
gene expression constitutively or conditionally [10–12]. Compared
to conventional shRNA molecules, gene silence mediated by
miRNA-shRNA has advantages. First, it has higher efficacy in
knock-down of target gene expression, for it works through the
existing natural mechanisms or pathways in cells which are used
by endogenous miRNA molecules [10]. Second, its expression can
be driven by polymerase II promoter, as that for endogenous
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RNAi to be more controllable.
M a m m a l i a na n i m a l s ,s u c ha sm i c e ,a r ee x t e n s i v e l yu s e d
models for the studies of pharmacokinetics or pharmacodynam-
ics in drug development. However, the remarkable species
differences in biological activity of cyptochromosme P450 (CYP)
enzymes limits the extent to which data obtained from animals
can be translated to humans [13–18]. CYP enzymes are heme-
containing monooxygenases responsible for the oxidative me-
tabolism of many endogenous and xenobiotic compounds, which
play critical roles in drug metabolism and are closely related to
toxicity or inefficacy of drugs [19–21]. Transgenic expression of
human CYP enzymes in animals has been recognized as an
effective method to correct the inter-specie disparity of CYP
enzymatic activity [16,18,22], however the counterparts of
animal endogenous CYPs usually show extensive overlaps in
substrate specificity and tissue distribution compared to that of
human [22,23]. Therefore, transgenic expression of a human
CYP in a background lacking or with largely reduced expression
of the orthologous counterparts of animal endogenous CYP
enzymes is considered to be an ideal strategy to analyze its
involvement in metabolism of target drugs, or its correlation to
drug toxicity or inefficacy [23].
Human cytochromose P450 3A (CYP3A), a subfamily of
cytochromosme P450 enzymes, is involved into the metabolism
of more than 50% of clinically available drugs, and exhibits
extensive overlaps in enzymatic activity compared to the
orthologous counterparts of mammalian animals. Therefore,
transgenic expression of human CYP3A in animals lacking the
expression of endogenous counterparts is of great value for drug
development [23,24]. Recently, a knock-out mouse lacking all the
muring CYP3A genes was generated by ES cell-based DNA
homologous recombination [23]. However, the CYP enzyme is a
superfamily consisting of many subfamilies and dozens of
members, it would be a highly costly, time-consuming and
labor-intensive process to knock-out CYP genes one by one
though ES cell-based technology. And beside, the ES cell-based
technology is currently not applicable to other mammalian species
of great importance in pharmacokinetics or pharmacodynamics
studies, such as rat, dog and monkey, mainly due to the lack of
established ES cell lines derived from these species. In contrast,
since RNAi is a conserved mechanism among eukaryotic
organisms, the RNAi-based gene knock-down technology, which
is at least theoretically applicable to all mammalian species,
provides an alternative method to disrupt endogenous CYP
enzyme expression.
This study was intended to try to knock down mammalian
endogenous CYP3A enzyme expression by RANi-based technol-
ogy in vivo using a miR-shRNA system, and thereby to find a
simple, effective and general method to generate mammalian
models lacking or with largely reduced endogenous CYP enzyme
expression. In this study, using a designed miR-shRNA simulta-
neously targeting four members of CYP3A, knock-down mice with
markedly reduced expression of CYP3A, the most abundant CYP
enzyme subfamily in mice which is considered to be the
orthologous counterpart of human CYP3A, was generated by
RNAi-based technology. We found that the transgenic miR-
shRNA targeting murine CYP3A, which was delivered by
lentiviral vector, suppressed CYP3A expression in a dose-
dependant and inheritable manner in mice. This work laid down
a foundation to further knock down other murine CYP3A genes or
other CYP subfamily genes, and also provide a basis to generate
CYP gene knock-down animals of other mammalian species of
biomedical importance.
Materials and Methods
Animals
Mice of FVBN inbred strain were used in this study, which were
purchased from SLAC Laboratory Animal Co.,Ltd (Shanghai,
China) and maintained under specific pathogen-free conditions in
Laboratory Animal Centre of our university. All the protocols
involving the use of animals were approved by the Institutional
Animal Care and Use Committee of Third Military Medical
University (Approval ID: SYXK-PLA-2007036).
Vector design and transgenic mouse production
The miR-shRNA sequences targeting CYP3A11, CYP3A16,
CYP3A41 and CYP3A44 were designed using the on-line RNAi
design algorithm at http://katahdin.cshl.org:9331_siRNA_RNAi.
cgi?type_shRNA as previously described [10]. To place the
shRNA sequences into miR30 context, a 97-mer sequence
containing the designed shRNA was retrieved through the RNAi
design algorithm, which was then subcloned into the site of pri-
miRNA area downstream the eGFP coding sequence (CDS) in
pRIME vector as previously described [10]. Then, the eGFP-
miRNA fragment was excised from the recombinant pRIME
vector and subcloned into the lentiviral vector FUW, and the
resulted recombinant vector was named FUW-eGFP-miR-shRNA
in this article.
To test the efficacy of designed shRNA sequences, lentiviral
vectors were packaged into lentiviral particles as previously
described [25] and infected primarily cultured mouse hepatic
cells derived from an adult female mouse. Each infection had three
duplicates. At 48 h post infection, using CellAmp
TM Whole
Transcriptome Amplification Kit (Takara, Dalian, China), cDNA
samples were prepared from infected or uninfected hepatic cells as
well. A pair of degenerate real-time PCR primers complementary
to mRNA sequences of CYP3A11, CYP3A44 and CYP3A41 was
designed, of which the sequences were 59-CTCAATGGTGTG-
TATATCCCC-39 (forward) and 59-GATGTTCTTAGACAC-
TGCC-39 (reverse) respectively. Using the prepared cDNA as
templates, the expression of CYP3A and the internal control gene
Rps18 were simultaneously detected in one PCR system. The
mixed PCR products were subjected to gel electrophoresis, and
semi-quantitation of CYP3A expression was obtained by compar-
ing the band density of the PCR product for CYP3A and that for
Rps 18 using the software Gel Pro.4.0. The primers for detecting
Rps18 were 59-AAATAGCCTTCGCCATCAC-39 (forward) and
59-TCACTCGCTCCACCTCATC-39 (reverse) respectively. The
two primer pairs for CYP3A and Rps 18 both corresponded to
different exons, and the sizes of PCR products were 421 and
129 bp respectively. The PCR reaction conditions were: 95uC
5 min; then entered the circle: 94uC3 0s ,5 4 uC3 0s ,7 2 uC3 0s ;
run 30 more circles, and then 72uC 8 min.
TheshRNAwithhigherefficacywasselectedtogeneratetransgenic
mice using FVBN mice by lentiviral transgenesis as previously
described [26,27]. Transgenic founder mice were screened by PCR
using genomic DNAs as templates. The sequences of the primer pair
for founder mouse screen were 59-GCGGATCCTACCGGTCGC-
CACCATGGTGAGCAA-39 (forward) and 59-GCGGCGCGC-
CCAATTGAAAAAAGTGATTTAATTTATACC-39 (reverse) re-
spectively, and the size of PCR product was 1012 bp. The PCR
conditionswere:95uC5 min;thenenteredthecircle:94uC30s,60uC
30 s, 72uC 1 min; run 30 more circles; then 72uC5m i n .
Real-time RT-PCR
Total RNA samples were prepared from livers of adult mice at
8-week age, treated with DNaseI and reversely transcribed as
Transgenic miR-shRNA Suppressed Mouse CYP3A
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of the internal control Rps18 quantitatively, the resulted cDNA
samples were subjected to real-time PCR using the same primer
pairs as mentioned above. The real-time PCR reaction systems for
both CYP3A and Rps 18 included: PCR primers (10 mM) 1 mL
each; SYBRH Premix Ex Taq
TM II(26)(Cat No.:DRR081A;
Takara, Dalian, China) 12.5 mL; cDNA preparation 2 mL; ddH2O
added up to 25 mL. The PCR conditions were: 95uC 3 min; then
entered cycles: 94uC 5 s, 60uC 30 s, plate read; run 39 more
cycles; then 72uC 3 min, 95uC 1 min, 60uC 1 min.
The relative expression of CYP3A was calculated using Pfaffl
equation: Ratio=(Etarget)
DCt(target)/(Eref)
DCt(ref), where Ratio stands
for the proportions of CYP3A expression of transgenic mice to that
of wild-type mice, Etarget for the E value (amplification efficiency)
of real-time PCR for CYP3A, Eref for the E value for internal
control (Rps 18) and DCt for the Ct difference value between the
Ct values for CYP3A(target) or Rps18(Ref) of transgenic and wild-
type mice.
To quantitatively detect the expression level of miR-shRNA
molecule in transgenic mice, using the same reversely transcribed
total RNA samples as above, real-time PCR was performed with
another primer pair corresponding to eGFP CDS and pri-miRNA
area of the transgene construct respectively. The primer sequences
were 59-CTACCTGAGCACCCAGTCCG-39 (forward) and 59-
TCCCAGCAAGTGTTTCCAAGAT-39 (reverse) respectively,
and the size of PCR product was 233 bp. The real-time PCR
system and reaction conditions for miR-shRNA were the same as
that for CYP3A, except that the melting temperature was 55uC.
To determine the copy numbers of miR-shRNA transcripts in
samples, the FUW-eGFP-miR-shRNA plasmid with defined copy
numbers diluted into cDNA samples prepared from wild-type
mouse livers at different concentrations was used as standard
sample to establish standard curve, thereby standard equation was
obtained. Based on the established standard equation, the copy
number of miR-shRNA transcript in each sample was calculated
using the corresponding Ct value. The copy number of Rps 18
mRNA in each sample was determined in the same way using the
primer pair as above. The miR-shRNA transcript copy number
was normalized to that of Rps 18 mRNA in the same sample, and
the resulted data was the relative miR-shRNA expression level.
Western blot analysis
Total protein was extracted from transgenic mouse livers using
Total Protein Extraction Kit (Promab, USA; Cat No.: SJ-200501)
as described in the manual. Total protein samples were subjected
to conventional SDS-PAGE electrophoresis, and then transferred
to NC membranes (PIERCE,USA; Catalog No.:88018) using a
transblot facility Mini Teans-Blot Elecreophoresis Transfer Cell
(Bio-Rad, USA; Catalog No:170- 3930). Western blot (WB) was
performed using Goat Anti-mouse CYP3A Antibody (Santa, USA;
Cat No.: sc-30621) as primary antibody to detect CYP3A
expression, and using Monoclonal Antibody to mouse GAPDH
(ProMab, USA; Cat No: Mab-2005079) as primary antibody to
detect the internal control GAPDH expression. The densities of
Western blot bands were detected using the software Gel Pro4.0.
Analysis of CYP3A enzymatic activity
Liver microsomes were prepared from untreated adult male
mice (aged 8–10 weeks) by differential centrifugation as previously
described [28,29], and the protein concentrations of the prepared
microsome suspensions were determined by Lowery method [30].
Using testosterone as the probe substrate, CYP3A activity in
mouse liver microsomes was measured through isocratic HPLC as
previously described [31]. Briefly, mouse liver microsome
suspensions were diluted with freshly prepared NAPDH genera-
tion system to be 1 mg/mL. Testosterone dissolved into DMSO
solution was added into 0.2 mL of the diluted liver microsome
suspension up to a final concentration of 100 mmol/L as the probe
substrate. After pre-incubation at 37uC for 5 min, 3 mL b-NADP/
b-NADPH solution containing 3% NaHCO3 was added to initiate
reaction. After incubation at 37uC for 30 min, 0.2 mL ice-cold
acetonitrile (Sigma, Cat No.: 34998; USA) was added into the
reaction mixture to terminate reaction. Thereafter, the reaction
mixtures were subjected to centrifuge and the supernatants were
used for HPLC analysis to detect the oxidative metabolite of probe
substrate. The CYP3A activity was assessed as concentrations of
the oxidative metabolite of probe substrate (6b-hydroxyl-testoster-
one).
Denaturing Gradient Gel Electrophoresis (DGGE) of RT-
PCR products of targeted CYP3A genes
The RT-PCR products subjected to DGGE were prepared
using the degenerate primer pair with complete complementarity
to all the three targeted CYP3A genes exhibiting expression in
adults (CYP3A11, CYP3A41 and CYP3A44) as mentioned above,
except that the reverse primer was fused 39 to a GC-clump. The
sequence of GC-clump was: 59-CGCCCGGGGCGCGCCCC-
GGGCGGGGCGGGGGCACGGGGGG-39. DGGE was per-
formed as previously described [32,33]. Briefly, DGGE was run
through 8% (wt/vol) polyacrylamide gels of the size 16-cm616-
cm61-mm. The gels contained a 30–50% gradient of urea and
formamide increasing in the direction of electrophoresis. The
100% denaturing solution was defined as 40% (vol/vol) formam-
ide and 7.0 M urea. Each lane was loaded with similar amount of
DNA. The gels were stained with AgNO3 after electrophoresis,
and then photographed using a digital camera (model D3100,
Nikone, Japan). After photographing, the DNA of each band was
extracted from gel, amplified by PCR using the degenerate primer
pair with no GC-clump and sequenced. The digital photo of the
gel was decolorized, and the intensities of DGGE bands were
detected using Quantity One 4.6.2 (Bio-rad) software as described
in the manual.
Results
shRNA design and generation of transgenic knock-down
mice
CYP3A is the most abundant subfamily of CYP enzymes in
mice [34]. In this study, shRNAs targeting several members of
CYP3A were designed using an on-line RNAi design algorithm as
described in Materials and Methods. Two shRNAs with high
scores were selected, of which the sequences were 59-AATTAA-
GAATGTGCTAGTGAAG-39 (shRNA1) and 59-AAGGTTTG-
CTCTCATGAATATG-39 (shRNA2) respectively. The unique-
ness of the two designed shRNAs was analyzed by BLAST. Data
showed that except the first nucleotide, which was included to
form the bubble structure of mature miRNA molecule, the 2–22nd
nucleotides of both shRNA1 and shRNA2 exhibited complete
complementarity to the mRNA sequences of CYP3A11,
CYP3A16 and CYP3A44, and moreover, that of shRNA1 showed
high complementarity to CYP3A41 with only one nucleotide
mismatch. In addition, the two shRNAs both exhibited no
homology to human CYP3A mRNA sequences, suggesting they
would not silence human CYP3A expression if human CYP3A
were transgenically expressed in the resulted knock-down mice.
The two shRNA sequences were placed into miR30 context
downstream eGFP CDS and thereby lentiviral vectors expressing
the miR-shRNAs, named as FUW-eGFP-miR-shRNA in this
Transgenic miR-shRNA Suppressed Mouse CYP3A
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efficacy of the two designed shRNAs in vitro, the FUW-eGFP-
miR-shRNA vectors expressing the miRNA-based versions of the
two designed shRNAs (miR-shRNA1 and miR-shRNA2) and an
unrelated miR-shRNA targeting luciferase gene (negative control)
were packaged into lentiviral particles, and infected primarily
cultured mouse hepatic cells. RT-PCR was performed to detect
CYP3A expression jn infected hepatic cells using a degenerate
primer pair complementary to all the three targeted CYP3As
which exhibit expression in adults (CYP3A11, CYP3A41 and
CYP3A44), and CYP3A16 expression was not detected because it
is not expressed in adults, but predominantly in fetus [35]. Results
showed that the CYP3A expression level in hepatic cells infected
with shRNA1 or shRNA2 was markedly lower than that of
uninfected cells (blank control) or cells infected with unrelated
miR-shRNA (negative control) (Fig. 2 A, B), suggesting that the
two designed shRNAs were both effective in inhibiting CYP3A
expression. The hepatic cells infected with shRNA1 exhibited the
lowest CYP3A expression level (Fig. 2 B), indicating that shRNA1
had a relatively higher efficiency in knock-down of target gene
expression. The CYP3A expression level of negative control was
comparable to that of blank control, suggesting that eGFP or
unrelated miR-shRNA expression did not disturb CYP3A
expression in cultured hepatic cells.
Figure 1. Structure of FUW-eGFP-miR-shRNA vector. The designed shRNA sequences targeting mouse CYP3A mRNAs were placed into human
miR30 context downstream eGFP coding sequence (CDS). The eGFP-miR-shRNA fragments were further inserted downstream the human Ubiquitin C
(UBC) promoter in the lentiviral vector FUW, as a result the eGFP-miR-shRNA fragment was under transcriptional control of human UBC promoter.
Arrows P1 and P2 indicates the positions of real-time PCR primers used to detect miR-shRNA expression, and P3 and P4 the primer positions for
transgenic founder mouse PCR screen.
doi:10.1371/journal.pone.0030560.g001
Figure 2. shRNA knock-down efficiency test in vitro and transgenic founder mouse production. A: CYP3A expression was detected by RT-
PCR in hepatic cells expressing the two designed shRNAs (shRNA1 and shRNA2), shRNA targeting luciferase gene (negative control) and untreated
hepatic cells (blank control) respectively. 1: DNA markers; 2: untreated hepatic cells (blank control); 3: hepatic cells infected with an unrelated shRNA
targeting luciferase gene (negative control); 4: hepatic cells infected with shRNA1; 5: hepatic cells infected with shRNA2. B: The CYP3A expression
level in hepatic cells expressing shRNA1 or shRNA2 was significantly lower than that of negative or blank control, and hepatic cells expressing shRNA1
exhibited the lowest CYP3A expression level. C: Transgenic mice were generated with the lentiviral vector expressing shRNA1, and four founder mice
were detected to be transgenic by PCR using genomic DNA as templates. D. The four transgenic founder mice displayed fluorescence of different
intensities. *: indicates statistic significance.
doi:10.1371/journal.pone.0030560.g002
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corresponding FUW-eGFP-miR-shRNA vector by lentiviral
transgenesis as previously described [26], and 4 founder mice
were detected to be transgenic by PCR (Fig. 2 C). The four
transgenic founder mice exhibited fluorescence of different
intensities as detected by exposing to 302 nm UV light emitted
from a UV light transmitter and observed through a red light filter
(Fig. 2 D). The founder mouse with the strongest fluorescence was
selected to breed for germline transmission. In parallel, the FUW-
eGFP-miR-shRNA vector expressing a miR-shRNA targeting
luciferase was also used to generate transgenic mice, which were
used as negative control (data not shown).
Transgenic miR-shRNA1 suppressed CYP3A expression in
a dose-dependent manner
Because miR-shRNA was co-transcribed with eGFP in one
transcript as a multi-cistron (Fig. 1), the eGFP expression level
should be quantitatively proportional to that of miR-shRNA
molecules. Therefore, stronger fluorescence should mean higher
miR-shRNA expression level and vice versa. On the basis of this
point, the four transgenic founder individuals, displaying fluores-
cence of different intensities, were all used to investigate the
correlation between the knock-down efficiency and miR-shRNA1
expression level.
The transgenic founder mouse exhibiting the strongest fluores-
cence was selected for breeding by mating with wild-type mice.
After germline transmission was confirmed, the four transgenic
founder individuals were all subjected to real-time RT-PCR
analysis (Fig. 3). Because mouse CYP3A expression exhibits
gender difference [35], two adult wild-type mice (one male and
one female) were included as blank controls for CYP3A expression
analysis, and the transgenic mice expressing an unrelated miR-
shRNA also included as negative control. Results showed that in
miR-shRNA1 transgenic mice, the relative CYP3A expression
level, which was normalized to that of wild-type control of the
same gender, was inversely correlated to the relative miR-shRNA1
expression level (Fig. 4A). Being consistent with our data for
cultured hepatic cells, the transgenic mice expressing an unrelated
miR-shRNA exhibited comparable CYP3A expression level to
wild-type mice, indicating that expression of eGFP or an unrelated
miR-shRNA did not disturb CYP3A expression in vivo either
(data not shown).
The CYP3A expression in the four transgenic founder
individuals was further detected by Western blot (WB). The
CYP3A protein expression level in each sample was calculated by
comparing the WB band density of CYP3A to that of the internal
control GAPDH. Data showed that the four transgenic founder
individuals, displaying fluorescence of different intensities, also
exhibited different levels of CYP3A protein (Fig. 4 B, C). The
relative CYP3A protein expression level, which was normalized to
that of the wild-type control of the same gender, was also inversely
correlated with the relative miR-shRNA1 expression levels (Fig. 4
D), being consistent with the data of real-time PCR analysis.
Transgenic miR-shRNA1 suppressed CYP3A expression
through germline transmission
The transgenic founder displaying the strongest fluorescence
was used for germline transmission by mating with a wild-type
individual before it was used for other analysis. F1 transgenic
individuals displaying variant intensities of fluorescence were
obtained as a result of lentiviral integrant segregation as previously
described [27,36]. Two F1 transgenic individuals, one male and
one female which displayed the strongest fluorescence among
littermates of the same gender, were selected for further germline
transmission by mating each other, and their offspring continued
to be bred in the same way over to F3 generation as previously
described [27]. The CYP3A expression levels in the breeding mice
of each generation were detected by WB. Data showed that the
CYP3A protein levels in the breeding mice of F1–F3 generations
were all markedly lower compared to those of controls (Fig. 5 A).
Moreover, the relative CYP3A protein expression level, which was
normalized to that of wild-type control of the same gender, was
comparable among different generations, but slightly decreased
over generations (Fig. 5 B). These data suggested that transgenic
miR-shRNA1 suppressed CYP3A expression in an inheritable
manner.
Lentiviral transgenesis usually results in multiple integrations,
and the expression level of transgene delivered by lentviral vector
is closely related to lentiviral integrant number[27]. Therefore, in
this study more lentiviral integrants might mean higher miR-
shRNA expression level and higher knock-down efficiency as a
result. For this reason, the knock-down efficiency per miR-
shRNA1 molecule was calculated by comparing the inhibition rate
of CYP3A expression to the relative miR-shRNA1 expression level
(the miR-shRNA1 transcript copy number normalized to that of
Rps 18 mRNA) in one individual. The inhibition rate of CYP3A
expression was calculated as the following: inhibition rate=(12-
CYP3A expression normalized to wild-type individual)6100%.
The inhibition rate per normalized miR-shRNA1 transcript copy
of each generation was the average value of the two breeding mice.
As shown in Fig. 5 C, the inhibition rate per normalized miR-
shRNA1 transcript copy remained relatively constant, but slightly
increased over generations (Fig. 5 C), further suggesting that
lentiviral transgenic miR-shRNA1 suppressed CYP3A expression
in an inheritable manner.
Because mouse CYP3A expression exhibits gender difference, to
investigate whether the knock-down efficacy observed in this study
also exhibited gender difference, we compared the inhibition rate
of CYP3A protein expression between male and female transgenic
mice using the data derived from the breeding mice of F1–F3
generations. Paired T-test was performed using the data of the two
breeding mice of each generation as a pair. Result showed that no
remarkable difference was observed for the inhibition rates
between male and female mice (P=0.9192). Actually, female
and male transgenic mice exhibited a very similar inhibition rate
(0.6460.096 vs 0.6560.076), indicating that the transgenic miR-
shRNA1 reduced CYP3A expression to a defined degree
regardless of gender.
Transgenic miR-shRNA1 remarkably reduced CYP3A
enzymatic activity
To further investigate the knock-down efficacy of transgenic
miR-shRNA1, CYP3A enzymatic activity in knock-down mice
was measured. Untreated adult male miR-shRNA1 transgenic,
unrelated miR-shRNA transgenic and wild-type mice of 8 week
age were subjected to CYP3A enzymatic analysis in parallel (five
mice/each group). To measure the CYP3A activity, testosterone
was added into liver microsome suspensions up to a defined
concentration (100 mmol/L) as probe substrate. Data showed that
the concentrations (mg/mL) of the oxidative metabolite of
testosterone (6b-hydroxyl-testosterone) in the liver microsome
suspensions of miR-shRNA1 transgenic mice were significantly
lower than those of wild-type mice (1.1160.71 vs 5.8561.74,
P=0.0005) or transgenic mice expressing an unrelated miR-
shRNA (1.1160.71 vs 5.962.4, P=0.00047) (Fig. 6), indicating
that the CYP3A enzymatic activity was markedly reduced in the
knock-down mice. In addition, the 6b-hydroxyl-testosterone
Transgenic miR-shRNA Suppressed Mouse CYP3A
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between unrelated miR-shRNA transgenic and wild-type mice
(5.8561.74 vs 5.962.4, P=0.9786) (Fig. 6), further indicating that
the expression of eGFP or an unrelated miR-shRNA had no effect
on CYP3A enzymatic activity, which was consistent with the data
for CYP3A expression analysis.
The targeted CYP3A genes in knock-down mice
exhibited similar characteristics in RT-PCR DGGE analysis
to those in controls
To address whether the three targeted CYP3A genes which
exhibit expression in adults were all suppressed in the knock-down
mice, mixed RT-PCR products of the three genes were prepared
using the degenerate primer pair as described above from randomly
selected knock-down mice and control (wild-type and unrelated
miR-shRNA transgenic) mice at 5-week age of both genders (Fig. 7
B). The mice of 5-week age were used because it had been reported
that at this age the three CYP3As were expressed in both male and
female [33]. The selected knock-down mice exhibited markedly
reduced overall CYP3A protein level compared to controls of the
same gender (Fig. 7 A). The mixed RT-PCR products were
subjected to DGGE analysis, a regular method designed to separate
homologous DNA fragments of the same length with base-pair
difference [33]. Data showed that the knock-down mice exhibited
almost the same DGGE band profile as controls of the same gender
(Fig. 7 C). In female group, CYP3A11, CYP3A41 and CYP3A44
were all detected, while in male group CYP3A11 and CYP3A41
detected. The ratios of the RT-PCR products of different CYP3As
(CYP3A11/CYP3A41 in male group and CYP3A11/CYP3A41/
CYP3A44 in female), which were estimated by comparing the
corresponding DGGE band intensities of each gene, were
comparable between knock-down and control mice of the same
gender (Fig. 7 D). These data indirectly indicated that the
transcriptional levels of the three targeted CYP3As were reduced
to a similar extent in knock-down mice.
Figure 3. Melting and standard curves of the real-time PCR systems for CYP3A, miR-shRNA1 and Rps18. The real-time PCR was
performed using cDNA samples prepared from the livers as templates. The standard equation of each real-time PCR system was y=20.3129x+8.19,
y=20.3279x+10.66 and y=20.3008x+8.18 respectively. The amplification efficiency (E value) of each system was 1.06, 1.18 and 1.00, and correlation
coefficients (r2 values) of the standard equations were 0.998, 0.997 and 0.994 respectively.
doi:10.1371/journal.pone.0030560.g003
Figure 4. Correlation between CYP3A expression level and that of miR-shRNA1. A: The correlation between the relative expression level of
CYP3A and that of miR-shRNA1 detected by real-time RT-PCR. The relative CYP3A expression was calculated by Pfaffl equation, and the resulted data
referred to the ratio of CYP3A expression in miR-shRNA1 transgenic mice to that of wild-type individual of the same gender. The relative miR-shRNA1
expression level was detected as the copy number of miR-shRNA1 transcript normalized to that of Rps 18 mRNA in the same sample. B: CYP3A
protein detected by Western blot in the livers of wild-type and miR-shRNA1 transgenic mice. The GAPDH protein was simultaneously detected as
internal control. WT-F: female wild-type mouse; WT-M: male wild-type mouse; 1–4: the four transgenic founder individuals displaying fluorescence of
different intensities. C: CYP3A protein levels in the four transgenic founders and wild-type mice. CYP3A protein level in each sample was calculated
by comparing the WB band density of CYP3A to that of GAPDH. D: The correlation between relative CYP3A protein expression level and that of miR-
shRNA1. Relative CYP3A protein expression level was the CYP3A protein level normalized to that of wild-type control of the same gender, which was
set as 1.
doi:10.1371/journal.pone.0030560.g004
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CYP3A is the most abundant CYP enzyme subfamily both in
human and mammalian animals, which are involved in the
metabolism of more than 50% of clinically available drugs for
humans. Therefore, CYP3A is the prior target to disrupt for
generation of animals lacking or with largely reduced endogenous
CYP expression. In this study, we designed a microRNA-based
shRNA (miR-shRNA) molecule simultaneously targeting four
members of mouse CYP3A subfamily: CYP3A11, CYP3A16,
Figure 5. Lentiviral transgenic miR-shRNA1 suppressed CYP3A expression through germline transmission. A: CYP3A protein detected
by WB in the two breeding mice of each generation. WT-1: female wild-type mouse; WT-2: male wild-type mouse; F1-1, F1-2: the two breeding mice
of F1 generation; F2-1, F2-2: the two breeding mice of F2 generation; F3-1, F3-2: the two breeding mice of F3 generation. B: Relative CYP3A
expression level in the breeding mice of F1–F3 generations. The relative CYP3A expression levels were calculated as described above, and the value
of each generation was the average of the two breeding mice. C: The inhibition rate of CYP3A expression per normalized miR-shRNA1 transcript copy
over generations. The value of each generation was also the average of the two breeding mice.
doi:10.1371/journal.pone.0030560.g005
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mice were subjected to CYP3A enzymatic activity analysis in parallel. The ages of used mice were 8–10 weeks. Analysis was performed using liver
microsome systems prepared from each group, and testosterone was added into the systems up to a defined concentration as the probe substrate.
The concentration of the oxidative metabolite of probe substrate (6b-hydroxyl-testosterone) was detected by HPLC analysis. Wild-type: wild-type
mice of FVBN strain; unrelated miR-shRNA: transgenic mice expressing a miR-shRNA targeting luciferase; miR-shRNA1: transgenic mice expressing the
miR-shRNA1 targeting CYP3A. * indicates statistic significance.
doi:10.1371/journal.pone.0030560.g006
Figure 7. DGGE analysis of the mixed RT-PCR products of targeted CYP3A genes. The mixed RT-PCR products were prepared using a
degenerate primer pair from randomly selected knock-down and control mice of 5-week age, and subjected to DGGE with similar amount of DNA
loaded into each lane. A: Overall CYP3A protein detected by WB in knock-down, wild-type (blank control) and unrelated miR-shRNA transgenic
(negative control) mice. B: The mixed RT-PCR products prepared from knock-down and control mice. C: The mixed RT-PCR products were subjected
to DGGE. D: The ratio of targeted CYP3A expression levels, estimated by comparing the corresponding DGGE band intensities of each gene. 1,3:
male knock-down mice; 4,6: male unrelated miR-shRNA transgenic mice; 7,9: male wild-type mice; 10,12: female knock-down mice; 13,15:
female unrelated miR-shRNA transgenic mice; 16,18: female wild-type mice.
doi:10.1371/journal.pone.0030560.g007
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homology to human CYP3A genes. Knock-down mice with
markedly reduced CYP3A expression were generated by trans-
genic expression of the designed miR-shRNA driven by a PolII
(human Ubiquin C) promoter. Using the four transgenic founder
individuals exhibiting different levels of miR-shRNA expression,
the correlation between the knock-down efficiency and miR-
shRNA expression level was directly investigated. Our data
showed that the transgenic miR-shRNA molecule suppressed
CYP3A expression in a dose-dependent manner in vivo,
suggesting that to generate knock-down animals with efficient
inhibition of target gene expression using this system, in addition
to design potent shRNA molecules, establishment of a transgenic
line with high miR-shRNA expression level is also necessary.
Germline transmission of knock-down efficacy is the perquisite
to establish a knock-down animal line lacking or with largely
reduced target gene expression. Our data showed that the CYP3A
expression levels in the transgenic offspring of F1–F3 generations,
which were all markedly lower than those of wild-type mice, were
comparable and moreover slightly decreased over generations. In
addition, the knock-down efficiency per miR-shRNA transcript
copy also slightly increased over generations. These results
confirmed that the lentiviral transgenic miR-shRNA suppressed
CYP3A expression in an inheritable manner, suggesting that the
lentiviral integrants expressing miR-shRNA were not subjected to
silence through germline transmission, which was consistent with
our previous data of lentviral transgene expression analysis [27].
The slight increase of knock-down efficiency over generation may
be due to the breeding strategy used in this study, through which
the lentiviral integrants exhibiting higher miR-shRNA expression
level were preferred to be transmitted through germline. On this
basis, this work provided a strategy to establish a transgenic line
with an inheritable and efficient knock-down of target gene
expression using lentiviral transgenic animals.
The knock-down efficacy observed in this study was further
confirmed by CYP3A enzymatic activity analysis. The average
CYP3A enzymatic activity in liver microsome suspensions of
knock-down mice was reduced to about twenty percent of that of
wild-type mice or transgenic mice expressing unrelated miR-
shRNA. The degree of CYP3A enzymatic activity reduction was
slightly higher than that of CYP3A protein reduction. One reason
for this may be that different members of CYP3A subfamily may
exhibits different activity or reaction kinetics in the metabolism of
substrates, which has already been observed in human [37].
Therefore, a certain degree of CYP3A protein reduction may
result in a higher degree of CYP3A enzymatic activity reduction if
the inhibited CYP3A enzymes exhibited a relatively higher
activity. Being consistent with the data of CYP3A expression
analysis, the expression of eGFP or unrelated miR-shRNA did not
affect mouse CYP3A enzymatic activity either, indicating that the
reduction of CYP3A enzymatic activity in knock-down mice was
exactly mediated by the designed transgenic miR-shRNA
molecule.
Due to the high homology of the three targeted CYP3A genes
which exhibit expression in adults (CYP3A11, CYP3A41 and
CYP3A44), we failed to design gene-specific primer pairs or
Taqman probes to detect each gene expression quantitatively one
by one. Besides, semi-quantitative analysis of each gene expression
by WB was not achieved either due to the lack of antibodies
targeting the three CYPs individually. By DGGE of the mixed
RT-PCR products of the three CYP3As prepared using a
degenerate primer pair, we separated the RT-PCR products of
the three genes. Data showed that the mixed RT-PCR products of
knock-down mice exhibited almost the same DGGE band profile
to those of control mice, and the ratios of RT-PCR products of the
three CYP3As were comparable between knock-down and control
mice. This result provided indirect evidence that the transcrip-
tional levels of the targeted CYP3As may be suppressed to a
similar extent in knock-down mice, even though the designed
transgenic miR-shRNA molecule had one nucleotide mismatch
with CYP3A41. However, this indirect evidence did not mean that
the targeted CYP3As were all actually reduced to a similar extent
on protein level. By DGGE analysis, CYP3A44 were not detected
in male group, which was not consistent with a previous report
[33] demonstrating that both CYP3A41 and CYP3A44 were
expressed in male C57BL6 mice of 5-week age. This inconsistence
may be due to the fact that a different mouse strain (FVBN) was
used in this work, and the CYP3A44 expression level in male
FVBN mice of 5-week age may be too low to be detected by
DGGE analysis.
Generation of knock-down animals lacking or with largely
reduced endogenous CYP3A expression is the ultimate goal of this
study. In this study, we designed a miR-shRNA simultaneously
targeting four members of CYP3A subfamily, but the remaining
three CYP3A members (CYP3A25, CYP3A57 and CYP3A59)
were not targeted, which may be the main reason for the residual
level of CYP3A protein or CYP3A activity. Among the remaining
three CYP3A members, CYP3A25 is considered to be the second
most abundant CYP enzyme in mice which exhibits a constitutive
expression with no gender or organ difference. Future work can be
focused on the knock-down of the remaining three CYP3A
members by the same strategy described in this work. Sequence
comparison indicates that the three mouse CYP3A genes exhibit
homology of a similar degree to that of the four CYP3A members
targeted in this study. Thus, one miR-shRNA can be designed to
disrupt the three CYP3A gene expressions. On this basis, a
‘‘bigenic’’ line simultaneously expressing two designed miR-
shRNA molecules can be established, and a knock-down mouse
line lacking or with largely reduced expression of all the CYP3A
genes can be obtained. In addition, considering that RNAi is a
highly conserved mechanism, and lentviral transgenesis is an
extremely efficient method for transgenic animal production
which has been proved to be applicable to a variety of mammalian
species including non-human primates [26,38–41], the strategy
described in this study can be further applied to other mammalian
species, especially those species of great value for drug develop-
ment which are highly refractory to traditional ES cell-based gene
knock-out technology, such as dog, minipig and non-human
primates. However, to use this system for these purposes, one point
should be taken into consideration that lentiviral transgenic miR-
shRNA can suppress endogenous CYP expression largely, but not
entirely. For many pharmacokinetic or pharmacodynamic studies
to evaluate drugs or investigate the relation of a particular human
CYP to a specific drug toxicity or inefficacy, low residual level of
endogenous CYP may not be a big hurdle. But for those
experiments requiring no endogenous CYP expression, this system
is not an optimal choice. Another limitation of this system is
multiple integrations of lentiviral transgene, which limits to
establish homozygous transgenic line with stable transgene
expression. However, our previous data [27] indicated that, by
selecting the individuals exhibiting the strongest transgene
expression as the breeding animals for each generation, a
‘‘transgenic colony’’ with relatively constant and high transgene
expression can be established after several generations of breeding
in this way consecutively. Therefore, on this basis a homozygous
line was not required. In addition, because this system contains a
marker gene being co-transcribed along with miR-shRNA
molecules, it would be convenient to use the transgenic animals
Transgenic miR-shRNA Suppressed Mouse CYP3A
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by the data of this work.
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